Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
about
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisCombination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report.Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer.Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patientsPredictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinibErlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study.Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Current status of DILD in molecular targeted therapies.Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epiDrug-induced hepatotoxicity in cancer patients - implication for treatment.The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging.
P2860
Q33599398-E04959AB-0993-475D-94BD-A17DE748E5ECQ34272887-808A4CE4-C025-4FE4-AFAF-4A90241C543BQ34342985-A669154D-25E2-4C7E-AD3C-367BC7EA281FQ34626688-317891EA-DBE1-4698-BF37-DF2E35141898Q35042354-7FF2C451-752E-4DD8-892A-BC717EA2829DQ35052012-994BA055-776D-416E-B59A-5BFBF06BE45FQ35623614-336B53D8-9EDD-4044-8FAC-BDDF04C9AFFEQ36084336-31E8382F-2442-47CB-9604-126FF4DD0E88Q36611511-E6DE5A2E-8EFC-4B96-96D6-532081E599D8Q36778198-7440E10B-E4AD-4C14-8B3A-FDC1F6705E04Q37002096-B40BA8EB-0B9F-4B37-AAF4-08307AC22D75Q37560742-A546F76C-5EA5-4F2F-825B-27CB8865F8C8Q37566846-60F29A69-56F6-4A9A-90F5-63DB902C8843Q37909352-13AB596A-2283-42E1-A203-CCE0E66AAE23Q37939200-F64317B7-A07A-40D1-98D4-F807AF2DBA90Q38059819-B149C17B-4AA8-47E2-ABBB-397E36125C35Q38095600-C245E6C3-10F9-4132-9D73-DD558027D4B2Q38357125-C9F1F037-B3D8-4152-951F-2922A0ACC1DCQ38543802-4F3C4C93-3970-448A-A322-FB842DDEB9C7Q38845891-D460E436-3EFC-4524-92CB-3B8F799F4039Q38891976-ACB8F6A0-332F-4956-9560-3FBAA668B142Q38930166-B31E415C-77DD-4390-9354-43A307F9A785Q51011218-485F3D46-F1F7-4067-9E4D-6750F17BE787Q51030222-C6593AEE-B877-4B92-BDDA-7172452C4340Q51291796-4CBFC394-0E90-4083-99E0-D9CE3D23279FQ52893820-BE028734-F450-461E-8906-F0A5CED43867Q53581780-2037B95C-575A-40F3-A053-65553E3F0946Q54162899-99A90BA9-2904-45E7-9257-905C7B54E1E3Q54979887-C5CDC51A-48F6-408A-AC99-6DFADE7D3A15
P2860
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@en
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@nl
type
label
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@en
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@nl
prefLabel
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@en
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@nl
P2093
P1476
Efficacy and safety of erlotin ...... lung cancer: a phase II study.
@en
P2093
Akira Yokoyama
Kaoru Kubota
Kaoru Matsui
Kazuhiko Nakagawa
Kazumasa Noda
Koji Takeda
Koshiro Watanabe
Masaaki Kawahara
Masahiro Fukuoka
Nagahiro Saijo
P304
P356
10.1097/JTO.0B013E31818D6702
P577
2008-12-01T00:00:00Z